Citations

Showing 10 of 108119 citations.

Propofol as a Drug of Diversion: Changing Disposal Practices to Reduce Risk
Ring, Michael T, Pfrimmer, Dale M.

Mayo Clinic

Critical Care Nurse | December 1, 2021 | Volume: 41 | Issue: 6 | Pages: 45-53

10.4037/ccn2021123 | PMID 34851389 Get It

BackgroundPropofol is a drug of diversion because of its high-volume use, lack of prescribed control mechanisms, and accessibility. As a result, intensive care unit nurses and other health care professionals are placed at unnecessary risk. Decreasing the risk of drug diversion can save lives, licenses, and livelihoods.Local ProblemObjectives were to reduce the risk of drug diversion and diminish the environmental impact of medication discarded down the sink. Disposing of residual propofol into activated carbon pouches was successful and sustainable in operating rooms at the study institution. Literature findings supported this intervention because of propofol’s potential for abuse, ongoing diversion events, ease of access, poor control mechanisms, lack of standardization, excessive waste, and ecological impact.MethodsThe intensive care unit with the highest propofol use was selected to replicate the propofol disposal process used in the operating rooms. Activated carbon pouches and bottle cap removal tools were located in each intensive care unit room at the nurses’ workstation for ease of use. Audits of unsecured waste bins and staff surveys of institutional policy awareness, disposal processes, barriers, and concerns were completed before and after the intervention.ResultsSurvey results determined significant concern for drug diversion risk. The pilot project displayed success: 44.1% of propofol bottles in waste bins were full before the intervention and 0% were full afterward.ConclusionFollowing institutional approval, this propofol disposal process was replicated in all intensive care units and the emergency department in the study institution.
21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
Kalinsky, Kevin, Barlow, William E., Gralow, Julie R., Meric-Bernstam, Funda, Albain, Kathy S., Hayes, Daniel F., Lin, Nancy U., Perez, Edith A., Goldstein, Lori J., Chia, Stephen K.L., Dhesy-Thind, Sukhbinder, Rastogi, Priya, Alba, Emilio, Delaloge, Suzette, Kelly, Catherine M., Ruiz-Borrego, Manuel, Gil-Gil, Miguel, Arce-Salinas, Claudia H., Brain, Etienne G.C., Lee, Eun-Sook, Pierga, Jean-Yves, Bermejo, Begoña, Ramos-Vazquez, Manuel, Jung, Kyung-Hae, Ferrero, Jean-Marc, Schott, Anne F., Shak, Steven, Sharma, Priyanka, Lew, Danika L., Miao, Jieling, Tripathy, Debasish, Pusztai, Lajos, Alba, Emilio , Tripathy, Debu , Kelly, Catherine M. , Dhesy‐Thind, Sukhbinder , Martin, Miguel , Hortobagyi, Gabriel N , Tripathy, Debasish , Dhesy-Thind, Sukhbinder , Alba, Emilio , Kalinsky, Kevin, Barlow, William E., Gralow, Julie R., Meric-Bernstam, Funda, Albain, Kathy S., Hayes, Daniel F., Lin, Nancy U., Perez, Edith A., Goldstein, Lori J., Chia, Stephen K.L., Rastogi, Priya, Delaloge, Suzette, Kelly, Catherine M., Ruiz-Borrego, Manuel, Gil-Gil, Miguel, Arce-Salinas, Claudia H., Brain, Etienne G.C., Lee, Eun-Sook, Pierga, Jean-Yves, Bermejo, Begoña, Ramos-Vazquez, Manuel, Jung, Kyung-Hae, Ferrero, Jean-Marc, Schott, Anne F., Shak, Steven, Sharma, Priyanka, Lew, Danika L., Miao, Jieling, Pusztai, Lajos

Mayo Clinic

New England Journal of Medicine | December 1, 2021 | Volume: 385 | Issue: 25 | Pages: 2336-2347

10.1056/nejmoa2108873 | PMID 34914339 Get It

Sister Mary Joseph nodule and the mystery behind its nomenclature
Subramaniam, Thirusivapragasam

Mayo Clinic

Clinical Anatomy | December 1, 2021 | Volume: 35 | Issue: 2 | Pages: 200-203

10.1002/ca.23815 | PMID 34851538 Get It

AbstractPhysicians, nurses, medical students, and nursing students from around the world are familiar with the Sister Mary Joseph nodule. It can appear in the subcutis of the umbilicus in persons who have malignancies of the stomach, pancreas, gynecological organs or urinary tract, or sometimes the respiratory tract. The mystery is how the term traveled overseas from a in Rochester, Minnesota, where Sister Joseph worked, to England, where it first appeared in publication in a textbook by a British surgeon, Hamilton Bailey. There is no record of Bailey ever meeting Sister Joseph or the Mayo brothers, or of his traveling to Mayo Clinic. This article explores the life of Sister Joseph, her influence on Dr William J. Mayo, and the life of Bailey.
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome
Baker, Alexander T. , Boyd, Ryan J. , Sarkar, Daipayan , Teijeira, Alicia , Chan, Chun Kit , Bates, Emily A. , Waraich, Kasim , Vant, John , Wilson, Eric , Truong, Chloe D. , Lipka‐Lloyd, Magdalena , Fromme, Petra , Vermaas, Josh V. , Williams, Dewight , Machiesky, LeeAnn , Nagalo, Bolni Marius , Coughlan, Lynda , Umlauf, Scott , Rizkallah, P.J. , Parker, Alan L. , Bates, Emily , Vermaas, Josh , Heurich, Meike , Nagalo, Bolni M, Coughlan, Lynda , Umlauf, Scott , Chiu, Po-Lin , Rizkallah, Pierre J , Cohen, Taylor S , Parker, Alan L , Singharoy, Abhishek , Borad, Mitesh J , Vant, John W , Fromme, Petra , Nagalo, Bolni , Baker, Alexander , Singharoy, Abhishek , Borad, Mitesh J. , Sarkar, Daipayan

Mayo Clinic

Science Advances | December 1, 2021 | Volume: 7 | Issue: 49 | Pages: No page available

10.1126/sciadv.abl8213 | PMID 34851659 Get It

We observe previously unknown interactions between clinically important adenovirus vector capsids, platelet factor 4, and CAR.
Preservation of neurocognitive function in the treatment of brain metastases
Parsons, Michael , Floyd, Scott , Brown, Paul D. , Parsons, Michael W , Peters, Katherine B. , Wefel, Jeffrey S.

Mayo Clinic

Neuro-Oncology Advances | December 1, 2021 | Volume: 3 | Issue: Supplement_5 | Pages: v96-v107

10.1093/noajnl/vdab122 | PMID 34859237 Get It

Abstract Neurocognitive function (NCF) deficits are common in patients with brain metastases, occurring in up to 90% of cases. NCF deficits may be caused by tumor-related factors and/or treatment for the metastasis, including surgery, radiation therapy, chemotherapy, and immunotherapy. In recent years, strategies to prevent negative impact of treatments and ameliorate cognitive deficits for patients with brain tumors have gained momentum. In this review, we report on research that has established the efficacy of preventative and rehabilitative therapies for NCF deficits in patients with brain metastases. Surgical strategies include the use of laser interstitial thermal therapy and intraoperative mapping. Radiotherapy approaches include focal treatments such as stereotactic radiosurgery and tailored approaches such as hippocampal avoidant whole-brain radiotherapy (WBRT). Pharmacologic options include use of the neuroprotectant memantine to reduce cognitive decline induced by WBRT and incorporation of medications traditionally used for attention and memory problems. Integration of neuropsychology into the care of patients with brain metastases helps characterize cognitive patterns, educate patients and families regarding their management, and guide rehabilitative therapies. These and other strategies will become even more important for long-term survivors of brain metastases as treatment options improve.
Index60 Identifies Individuals at Appreciable Risk for Stage 3 Among an Autoantibody-Positive Population With Normal 2-Hour Glucose Levels: Implications for Current Staging Criteria of Type 1 Diabetes
Nathan, Brandon M. , Jacobsen, Laura M. , Sims, Emily K. , Palmer, Jerry P., Bocchino, Laura E., Geyer, Susan, Sosenko, Jay M. , Redondo, María J. , Ismail, Heba M. , Skyler, Jay S.

Mayo Clinic

Diabetes Care | December 1, 2021 | Volume: 45 | Issue: 2 | Pages: 311-318

10.2337/dc21-0944 | PMID 34853027 Get It

OBJECTIVE We assessed whether Index60, a composite measure of fasting C-peptide, 60-min C-peptide, and 60-min glucose, could improve the metabolic staging of type 1 diabetes for progression to clinical disease (stage 3) among autoantibody-positive (Ab+) individuals with normal 2-h glucose values (<140 mg/dL). RESEARCH DESIGN AND METHODS We analyzed 3,058 Type 1 Diabetes TrialNet Pathway to Prevention participants with 2-h glucose <140 mg/dL and Index60 <1.00 values from baseline oral glucose tolerance tests. Characteristics associated with type 1 diabetes (younger age, greater Ab+, higher HLA DR3-DQ2/DR4-DQ8 prevalence, and lower C-peptide) were compared among four mutually exclusive groups: top 2-h glucose quartile only (HI-2HGLU), top Index60 quartile only (HI-IND60), both top quartiles (HI-BOTH), and neither top quartile (LO-BOTH). Additionally, within the 2-h glucose distribution of <140 mg/dL and separately within the Index60 <1.00 distribution, comparisons were made between those above or below the medians. RESULTS HI-IND60 and HI-BOTH were younger, with greater frequency of more than two Ab+, and lower C-peptide levels, than either HI-2HGLU or LO-BOTH (all P < 0.001). The cumulative incidence for stage 3 was greater for HI-IND60 and HI-BOTH than for either HI-2HGLU or LO-BOTH (all P < 0.001). Those with Index60 values above the median were younger and had higher frequency of two or more Ab+ (P < 0.001) and DR3-DQ2/DR4-DQ8 prevalence (P < 0.001) and lower area under the curve (AUC) C-peptide levels (P < 0.001) than those below. Those above the 2-h glucose median had higher AUC C-peptide levels (P < 0.001), but otherwise did not differ from those below. CONCLUSIONS Index60 identifies individuals with characteristics of type 1 diabetes at appreciable risk for progression who would otherwise be missed by 2-h glucose staging criteria.
A Man with Exertional Dyspnea and Diffuse Bronchial Wall Thickening
Stultz, Benjamin R. , Ryu, Jay H. , Edell, Eric S., Kelm, Diana J. , Ryu, Jay H , Stultz, Benjamin R. , Edell, Eric S., Kelm, Diana J

Mayo Clinic

Annals of the American Thoracic Society | December 1, 2021 | Volume: 18 | Issue: 12 | Pages: 2084-2089

10.1513/annalsats.202105-545cc | PMID 34851243 Get It

Cytoreductive Surgery of the Primary Tumor in Metastatic Adrenocortical Carcinoma: Impact on Patients’ Survival
Srougi, Victor , Daher, Marilyne , Lee, Jeffrey E. , Graham, Paul H. , McKenzie, Travis J. , Sada, Alaa , Bourdeau, Isabelle , Poirier, Jonathan , Vaidya, Anand , Abbondanza, Tiffany, Kiernan, Colleen M., Rao, Sarika , Sachithanandan, Nirupa , Hoff, Ana O. , Chambô, Jose L, Almeida, Madson Q. , Fragoso, Maria Candida Barisson Villares , Bancos, Irina , Henriquez, Andres, Rao, Sarika N , Hamidi, Oksana , Almeida, Madson Q , Bancos, Irina , Karam, Jose Antonio , Henriquez, Andres, Hamidi, Oksana , Habra, Mouhammed Amir

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | December 1, 2021 | Volume: 107 | Issue: 4 | Pages: 964-971

10.1210/clinem/dgab865 | PMID 34850915 Get It

Abstract Context The role of cytoreduction of adrenocortical carcinoma (ACC) remains poorly understood. Objective To analyze the impact of cytoreductive surgery of the primary tumor in patients with metastatic ACC. Design and Setting We performed a multicentric, retrospective paired cohort study comparing the overall survival (OS) in patients with metastatic ACC who were treated either with cytoreductive surgery (CR group) or without cytoreductive surgery (no-CR group) of the primary tumor. Data were retrieved from 9 referral centers in the American-Australian-Asian Adrenal Alliance collaborative research group. Patients Patients aged ≥18 years with metastatic ACC at initial presentation who were treated between January 1, 1995, and May 31, 2019. Intervention Performance (or not) of cytoreductive surgery of the primary tumor. Main outcome and measures A propensity score match was done using age and the number of organs with metastasis (≤2 or >2). The main outcome was OS, determined from the date of diagnosis until death or until last follow-up for living patients. Results Of 339 patients pooled, 239 were paired and included: 128 in the CR group and 111 in the no-CR group. The mean follow-up was 67 months. Patients in the no-CR group had greater risk of death than did patients in the CR group (hazard ratio [HR] = 3.18; 95% CI, 2.34-4.32). Independent predictors of survival included age (HR = 1.02; 95% CI, 1.00-1.03), hormone excess (HR = 2.56; 95% CI, 1.66-3.92), and local metastasis therapy (HR = 0.41; 95% CI, 0.47-0.65). Conclusion Cytoreductive surgery of the primary tumor in patients with metastatic ACC is associated with prolonged survival.
National Comprehensive Cancer Network investigational drug service consensus recommendations
Amin, Sapna, Polley, Stephen , DeFrates, Sean, Finnes, Heidi D. , Kinsman, Katharine, MacDonald, Elyse A. , Dean, Latanya, DeWitt, Lorri L., Harvey, Caroline , Leung, Tzewah Vivian, Moll, Emily A, O’Neill, Gerald P. , Redic, Kimberly, Park, Sharon F, Harvey, Caroline, Johnston, Susan S.

Mayo Clinic

American Journal of Health-System Pharmacy | December 1, 2021 | Volume: 79 | Issue: 6 | Pages: 486-491

10.1093/ajhp/zxab455 | PMID 34849539 Get It